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SESSION II
ARTHRITIS/OSTEOPORISIS
ARTHRITIS—Clinical Outcomes Studies
PAR1
TREATMENT ADHERENCE WITH TNF-
INHIBITORS AND METHOTREXATE IN
PATIENTS WITH RHEUMATOID ARTHRITIS IN A
LARGE STATE MEDICAID PROGRAM
Singh G1, Mithal A2, Kavanaugh A3
1Stanford University, Palo Alto, CA, USA; 2Institute for Clinical
Outcomes Research and Education, Woodside, CA, USA;
3UCSD, La Jolla, CA, USA
TNF inhibitors signiﬁcantly reduce disease activity and
morbidity in patients with RA, but there are few studies
on the use of these drugs in actual clinical practice.
OBJECTIVES: To evaluate treatment adherence with
TNF inhibitors and methotrexate in patients with
rheumatoid arthritis. METHODS: We studied new drug
starts with TNF inhibitors and methotrexate in RA
patients enrolled in the California Medicaid program for
the period 1999–2002. Drug discontinuation was deﬁned
if there was no prescription reﬁll for 2 consecutive pre-
scription periods (60 days for methotrexate and etaner-
cept and 16 weeks for inﬂiximab). Treatment persistence
was assessed in terms of the number of days of continu-
ous therapy. RESULTS: A total of 77,757 patients had 
a diagnosis of RA during 1999–2002. Of these, 8224
patients had a new drug start on methotrexate, and 2700
on TNF inhibitors (1251 for inﬂiximab and 1449 for
etanercept). Patients on TNF inhibitors were more likely
to be female and non-white. During the study period
(1999–2002), 82.3% of patients who started on
methotrexate switched or discontinued their therapy, 
or added another drug (TNF inhibitor or leﬂunomide).
Of the 2700 new drug starts on TNF inhibitors, 1649
patients (61.1%) discontinued or switched therapy
(78.1% for etanercept, 41.3% for inﬂiximab, p < 0.001
compared to methotrexate). The time to discontinuation
was signiﬁcantly higher in patients on TNF inhibitors
(460.7 + 10.4 days) compared to those on methotrexate
(364.5 + 4.5 days). Cox proportional hazard model
analysis showed that after adjusting for age, gender and
ethnic origin, the treatment discontinuation was still sta-
tistically signiﬁcantly different between the two groups 
(p < 0.001). CONCLUSIONS: RA patients started on
TNF inhibitors tend to stay signiﬁcantly longer on
therapy and have a lower rate of discontinuation com-
pared to those started on methotrexate, perhaps indicat-
ing a better effectiveness/toxicity trade-off.
PAR2
TOWARDS VALUING PREFERENCES FOR
DISTRIBUTION OF HEALTH GAIN IN HIP AND
KNEE DISEASE
Payne K, Davies LM, Fargher E
Manchester University, Manchester, Gtr. Manchester, United
Kingdom
OBJECTIVES: To identify key attributes perceived as
important components of decisions to seek, provide or
prioritise treatment for hip and knee disease and assess
whether equity weights that value preferences for the dis-
tribution of health gain should be included in economic
evaluation of joint replacement in the UK. METHODS:
Face-to-face semi-structured interviews were used to iden-
tify factors that are or should be important in the deci-
sions to seek or provide joint replacement surgery. The
study sample comprised 18 patients with hip or knee
disease, 4 general practitioners, 5 hospital clinicians and
6 support staff. A thematic framework approach was
used to identify the key attributes affecting access to treat-
ments and distribution of health gain. A sample of 25
University staff was asked to rank the factors according
to whether they should inﬂuence treatment decisions to
provide joint replacement. RESULTS: Respondents inter-
viewed identiﬁed 17 factors they believed did inﬂuence
treatment decisions. These were ranked according to
whether they should inﬂuence treatment decisions. The
factors and% of respondents who thought they should be
included in the decision making process were: pain
(100%), mobility (100%), potential to beneﬁt (92%),
able to return to normal activities (84%), number of years
in pain (84%), presence of other diseases (72%), patient
cares for another (64%), age (56%), weight (52%), takes
control of own health (44%), cost (28%), type of job
(28%), type of accommodation (28%), healthy lifestyle
(24%), demanding personality (4%), postal address (0%)
and ethnic class (0%). CONCLUSIONS: The results indi-
cate that respondents felt severity of illness and potential
for health gain should be the most important factors for
treatment decisions. However, other factors concerning
the distribution of health gain and access were considered
important, indicating that equity weights are valid com-
ponents of instruments to value preferences for joint
replacement in the UK.
ARTHRITIS—Cost Studies
PAR3
EVALUATING THE IMPACT OF
REIMBURSEMENT OF NON SELECTIVE COX2
INHIBITORS ON TOTAL DISPENSING OF
SELECTED NSAID AND SELECTED DRUGS FOR
ACID RELATED DISORDERS
Trindade R, Lourenço A
INFARMED, Lisbon, Portugal
OBJECTIVE: To evaluate the NHS consumption evolu-
tion for non selective Cox2 inhibitors (NSAID) and Drugs
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for Acid Related Disorders (DARD) after the reimburse-
ment of rofecoxib and celecoxib. The substances con-
sidered were: NSAID: aceclofenac, acemetacin,
diclofenac, ibuprofen, indometacin, meloxicam, nabume-
ton, naproxen, nimesulide, piroxicam, tenoxicam; Proton
Pump Inhibitors: omeprazol, pantoprazol, lansoprazol,
rabeprazol, esomeprazol; H2 Receptor Antagonists: cime-
tidine, famotidine, nizatidine, ranitidine; misoprolol and
sucralfate were also studied. METHODS: Using data of
reimbursed medicines dispensed in the NHS (in DDD
units) from January 1995 to June 2001, modelling was
performed using SARIMA models. Intervention variables
were used to evaluate the inﬂuence of the reimburse-
ment of Cox2 inhibitors on overall NSAID and DARD
consumption. RESULTS: NSAID overall consumption
increased for the considered time period from 50.49
DDD/1.000 inhabitants/day in year 2000 to 62.35
DDD/1.000 inhabitants /day 1° semester 2001. DARD
consumption also increased from 24.87 DDD/1.000
inhabitants/day to 28 DDD/1.000 inhabitants /day during
the above mentioned period of time. CONCLUSIONS:
The global dispensing of selected NSAID in 1° semester
2001 faced a total increase above the projected value. The
Cox2 inhibitors appear to have an add-on effect, rather
than a substitutive effect on already existing therapies.
Moreover we did not observe decrease on DARD con-
sumption patterns.
PAR4
ETANERCEPT VERSUS INFLIXIMAB PLUS
METHOTREXATE IN RHEUMATOID ARTHRITIS:
A COST-EFFECTIVENESS ANALYSIS FROM THE
ITALIAN NHS PERSPECTIVE
Lopatriello S, Berto P
PBE Consulting,Verona, Italy
OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic
disease, whose social burden is mostly related to costs
that increase with the progression of illness severity and
related disability. Thus it is possible that early treatment
induces signiﬁcant cost savings. Recently favourable cost-
effectiveness ratios were demonstrated for Etanercept
(ETA) versus Inﬂiximab plus Methotrexate (INFLI +
METHO) for early RA treatment, in severe US patients
previously untreated with METHO. An adaptation of the
US model to Italy was undertaken, in order to evaluate
cost-effectiveness of ETA, in the Italian National Health
care System (NHS) perspective (direct medical costs).
METHODS: Cost-effectiveness analysis compared ETA
25mg twice weekly with INFLI 3mg/kg or 10mg/kg
(mean patient weight 74Kg was assumed, from clinical
trials) q4 or q8 weeks plus oral METHO (16mg/week).
Time horizon was established at two years, according to
published long-term follow-up clinical data. Also, drug
dosages, efﬁcacy and probabilities of events were based
on published clinical trial data. Market prices were
applied for medication costs plus ofﬁcial tariffs for IV
administration and monitoring for INFLI and METHO.
For sepsis as a major adverse event, the NHS hospital
tariff was used. The total per patient cost was then cal-
culated and the cost-effectiveness ratio was expressed as
cost/patient to prevent radiographycally detected RA pro-
gression. RESULTS: Total cost/patient for ETA was lower
compared to INFLI + METHO at different dosages
(respectively, €25,931 vs from €44,745 to €119,215,
depending on INFLI schedule), with the only exception
of INFLI 3mg/kg q8 weeks (€24,189). Cost-effectiveness
ratio (cost/patient successfully treated) was €41,160 for
ETA vs values in the range of €56,122 to €218,743 
for INFLI + METHO. CONCLUSIONS: ETA was found
dominant (less costly and more effective) versus 3 differ-
ent dosages of INFLI + METHO, and showed a positive
cost-effectiveness ratio versus INFLI 3mg/kg q8 weeks, in
the perspective of the Italian NHS.
PAR5
THE TOTAL COSTS OF TREATMENT WITH
VALDECOXIB COMPARED TO GENERIC
DICLOFENAC ARE SIMILAR IN PATIENTS WITH
RHEUMATOID ARTHRITIS IN GERMANY
von Scheele B1, DePlatchett J1, Gaffney L2, Peña BM3,
Niculescu L3
1RTI Health Solutions, Research Triangle Park, NC, USA; 2RTI
Health Solutions, Manchester, United Kingdom; 3Pﬁzer Inc,
New York, NY, USA
OBJECTIVES: To conduct a cost-consequence analysis
evaluating the treatment cost difference between valde-
coxib and diclofenac in rheumatoid arthritis (RA) treat-
ment from the perspective of German Sickness funds.
METHODS: Health care resource utilization data were
prospectively collected in a double-blind randomized trial
of oral valdecoxib 20mg QD (n = 246) versus diclofenac
75mg BID (n = 237) of adult patients with RA in 26
countries. The study demonstrated that valdecoxib has a
superior GI safety proﬁle and comparable efﬁcacy to
diclofenac. The Health care resource data were costed
using published German sources. Information evaluated
medications, hospitalizations, unscheduled consultations
with Health care professionals and use of diagnostic and
medical procedures. Pharmacy costs of valdecoxib and
generic diclofenac were included. In-depth analyses were
conducted to explore the cost-difference attributable to
gastrointestinal (GI) serious adverse events (GI-SAEs).
The results are presented in cost per patient during the
study period and cost per patient per day of treatment in
order to adjust for the lower withdrawal rates with valde-
coxib. RESULTS: The fewer hospitalization days in
valdecoxib patients translated into signiﬁcantly lower
hospitalization cost per patient for valdecoxib with a 
cost difference of €138.17 (95% conﬁdence interval [CI]:
€282.84, €10.58). The total Health care costs per patient
over a 6-month period for valdecoxib (€659.45) com-
pared to diclofenac (€549.31) showed a cost difference 
of €110.14 (95% CI: €70.33, €290.62). Accounting for
the different withdrawal rates (patients stayed longer on
